quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:00:00·59d
PRRelease
Beam Therapeutics Inc. logo

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

BEAM· Beam Therapeutics Inc.
Health Care
Original source

Companies

  • BEAM
    Beam Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 20UpdateCanaccord Genuity$74.00
  • Oct 9UpdateJefferies$41.00
  • Mar 28UpdateBofA Securities$42.00
  • Mar 10UpdateScotiabank$40.00
  • Jan 29UpdateCantor Fitzgerald-
  • Nov 6UpdateLeerink Partners$39.00

Related

  • SEC6d
    SEC Form DEFA14A filed by Beam Therapeutics Inc.
  • SEC6d
    SEC Form DEF 14A filed by Beam Therapeutics Inc.
  • SEC9d
    SEC Form 144 filed by Beam Therapeutics Inc.
  • INSIDER17d
    SEC Form 4 filed by Evans John M.
  • INSIDER17d
    SEC Form 4 filed by Simon Amy
  • INSIDER17d
    SEC Form 4 filed by Bellon Christine
  • INSIDER17d
    SEC Form 4 filed by Cavanagh Bethany J
  • INSIDER17d
    SEC Form 4 filed by Ciaramella Giuseppe
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022